CERA

Science and Research

ADVISE: Adalimumab vs. Conventional Immunosuppression for Corticosteroid-sparing for Uveitis Trial

The ADVISE Trial is a randomised, parallel-treatment, comparative effectiveness trial. 

Overview

The ADVISE Trial is a randomised, parallel-treatment, comparative effectiveness trial.

It aims to compare the relative effectiveness of adalimumab compared to conventional immunosuppression at controlling ocular inflammation caused by uveitis, while permitting tapering and discontinuation of oral corticosteroids.

  • Principal Investigator
Associate Professor Lyndell Lim

Learn more

View this study at ClinicalTrials.gov

This international database listing provides more detailed information about this study.